Status:
COMPLETED
Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
Lead Sponsor:
Mirati Therapeutics Inc.
Conditions:
Urothelial Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Mocetinostat is an orally administered histone deacetylase (HDAC) inhibitor. This study is a Phase 2 trial evaluating the efficacy of mocetinostat in patients that have advanced urothelial carcinoma t...
Detailed Description
To be eligible for this study, patient tumor testing must demonstrate a genetic alteration resulting in the loss of function of the Histone Acetyltransferase (HAT) family genes, CREBBP and/or EP300, i...
Eligibility Criteria
Inclusion
- Diagnosis of urothelial carcinoma
- Metastatic or locally advanced disease
- Prior chemotherapy that included a platinum agent
- Test results showing genetic change in tumor gene for CREBBP and/or EP300
- At least one tumor that can be measured
Exclusion
- Uncontrolled tumor in the brain
- Impaired heart function
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2016
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT02236195
Start Date
October 1 2014
End Date
July 1 2016
Last Update
September 1 2017
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama
Birmingham, Alabama, United States, 35294
2
City of Hope National Medical Center
Duarte, California, United States, 91010
3
Florida Cancer Specialists
Fort Myers, Florida, United States, 33905
4
University of Chicago
Chicago, Illinois, United States, 60637